Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue
10.1158/1535-7163.MCT-11-0044
Saved in:
Main Authors: | Novotny-Diermayr, V., Sausgruber, N., Loh, Y.K., Pasha, M.K., Jayaraman, R., Hentze, H., Yong, W.-P., Goh, B.-C., Toh, H.-C., Ethirajulu, K., Zhu, J., Wood, J.M. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Article |
Published: |
2014
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/110765 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies
by: Yong, W.P., et al.
Published: (2014) -
The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia
by: Rauzan M., et al.
Published: (2020) -
Preclinical metabolism and disposition of SB939 (pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics
by: Jayaraman, R., et al.
Published: (2014) -
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
by: Hart, S., et al.
Published: (2014) -
宋太宗(939-997)与宋初的政治 = Emperor Taizong (939-997) and the politics of early Song Dynasty
by: 钟国荣, et al.
Published: (2011)